B Malone, "An AI Platform for Designing Personalized Neoantigen Vaccines Which Induce Polyepitopic Immune Responses" 2024; The 7th International Neoantigen Summit

A. Lalanne, C. Jamet, J.-P. Delord, C. Ottensmeier, C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M. Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke, N. Yamagata, Y. Tanaka, K. Onoguchi, I. Pait, B. Malone, O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K. Bendjama, O. Lantz; "Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV-negative Head and Neck cancers" AACR. 2024; LB401.

K Bendjama, "AI Empowered Infectious Disease Vaccine Development" 2024; The World Vaccine Congress Washington

K Bendjama, "Towards realization of AI drug development:Comprehensive process workflow for the Commercial Use of Personalized Cancer Vaccines" 2024; NextGen Therapies Industry Working Group Summit

Sverchkova, A., Burkholz, S., Rubsamen, R. et al. Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response. BMC Med Genomics 17, 37 (2024).

Gainullin M, Federico L, Røkke Osen J, Chaban V, Kared H, Alirezaylavasani A, Lund-Johansen F, Wildendahl G, Jacobsen J-A, Sarwar Anjum H, Stratford R, Tennøe S, Malone B, Clancy T, Vaage JT, Henriksen K, Wüsthoff L and Munthe LA (2024) People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination. Front. Immunol. 14:1235210. doi: 10.3389/fimmu.2023.1235210

Nielsen, M., Monberg, T., Sundvold, V., Albieri, B., Hovgaard, D., Petersen, M. M., … Svane, I. M. (2023). LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma. OncoImmunology, 13(1).

Federico L, Malone B, Tennøe S, Chaban V, Osen JR, Gainullin M, Smorodina E, Kared H, Akbar R, Greiff V, Stratford R, Clancy T and Munthe LA (2023) Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence. Front. Immunol. 14:1265044. doi: 10.3389/fimmu.2023.1265044

Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O and Clancy T (2023) The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. Front. Immunol. 14:1226445. doi: 10.3389/fimmu.2023.1226445

NEC OncoImmunity to Present Developments in the Infectious Diseases at 21st Awaji International Forum on Infection and Immunity, 2023

Ellingsen EB, O'Day S, Mezheyeuski A, Gromadka A, Clancy T, Kristedja TS, Milhem M, Zakharia Y. Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial. Clin Cancer Res. 2023 Aug 15;29(16):3026-3036. doi: 10.1158/1078-0432.CCR-23-0416. PMID: 37378632; PMCID: PMC10425723.

H Komuro, S Shinohara, Y Fukushima, A Demachi-Okamura, D Muraoka, K Masago, T Matsui, Y Sugita, Y Takahashi, R Nishida, C Takashima, T Ohki, Y Shigematsu, F Watanabe, K Adachi, T Fukuyama, H Hamana, H Kishi, D Miura, Y Tanaka, K Onoue, K Onoguchi, Y Yamashita, R Stratford, T Clancy, R Yamaguchi, H Kuroda, K Doi, H Iwata, H Matsushita, "Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer." Journal for Immunotherapy of Cancer. 2023; 11(8): e007180.

山下慶子, "ワクチン開発へのAIの応用", 2023; 第39回日本DDS学会学術集会

Federico L, Tvedt THA, Gainullin M, Osen JR, Chaban V, Lund KP, Tietze L, Tran TT, Lund-Johansen F, Kared H, Lind A, Vaage JT, Stratford R, Tennøe S, Malone B, Clancy T, Myhre AEL, Gedde-Dahl T and Munthe LA (2023) Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study. Front. Immunol. 14:1210899. doi: 10.3389/fimmu.2023.1210899

Christian H.H. Ottensmeier, Jean-Pierre Delord, Ana Lalanne, Olivier Lantz, Camille Jamet, Annette TAVERNARO, Maud Brandely-Talbot, Benoît Grellier, Berangere Bastien, Hakim Makhloufi, Thierry Huss, Yoshiko Yamashita, Kousuke Onoue, Naoko Yamagata, Yuki Tanaka, Brandon Malone, Oliver Baker, Eric Quemeneur, Kaidre Bendjama, Christophe Le Tourneau. "Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma." ASCO. 2023; 6082-6082.

北村哲, "NECのAI創薬事業", 2023; 第72回高分子学会年次大会

F Grazioli, P Machart, A Mösch, K Li, L V Castorina, N Pfeifer, MR Min, "Attentive variational information bottleneck for TCR–peptide interaction prediction." Bioinformatics 39.1 (2023): btac820.

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. J Transl Med. 2022 Sep 11;20(1):419. doi: 10.1186/s12967-022-03624-z. PMID: 36089578; PMCID: PMC9465869.

Tennøe S, Gheorghe M, Stratford R, Clancy T. The T Cell Epitope Landscape of SARS-CoV-2 Variants of Concern. Vaccines (Basel). 2022 Jul 14;10(7):1123. doi: 10.3390/vaccines10071123. PMID: 35891287; PMCID: PMC9315645.

M Block, J Delord, C Ottensmeier, C Tourneau, A Lalanne, O Lantz, K Knutson, G Lacoste, A Tavernaro, M Brandely, N Silvestre, B Grellier, Y Yamashita, K Onoue, N Yamagata, E Quemeneur, and K Bendjama, "Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients." AACR. Cancer Research. 2022; 82(12 Suppl): CT182.

J Delord, M Block, C Ottensmeier, G Colon-Otero, C Tourneau, A Lalanne, C Jamet, O Lantz, K Knutson, G Lacoste, A Tavernaro, M Brandely-Talbot, N Silvestre, B Grellier, B Malone, Y Tanaka, K Onoue, Y Yamashita, E Quemeneur, and K Bendjama. "Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC)." ASCO. 2022; 2637-2637.

Anzar I, Sverchkova A, Samarakoon P, et al. Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants. HLA. 2022; 99(4): 313-327. doi:10.1111/tan.14562

山下慶子, "個別化がんワクチン療法に向けたAIによるネオアンチゲンの予測", 2021; 第57回日本肝癌研究会

山下慶子, "個別化がんワクチン療法に向けたAIによるネオアンチゲンの予測", 2021; 第13回日本血液疾患免疫療法学会学術集会

山下慶子, Kaidre BENDJAMA, "個別化がんワクチン療法に向けたAIによるネオアンチゲンの予測", 2021; 第18回日本免疫治療学会学術集会

山下慶子, "個別化がんワクチン療法に向けたAIによるネオアンチゲンの予測", 2021; 国際医薬品開発展2021

山下慶子, "個別化がんワクチン療法に向けたAIによるネオアンチゲンの予測", 2021; 第4回ソーシャル・スマートデンタルホスピタル（S2DH）シンポジウム

B Malone, B Simovski, C Moliné, J Cheng, M Gheorghe, H Fontenelle, I Vardaxis, S Tennøe, JA Malmberg, R Stratford, and T Clancy, "Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs." Scientific reports. 2020; 10(1): 1-14.

B Malone, C Tosch, B Grellier, K Onoue, T Sztyler, K Rittner, Y Yamashita, E Quemeneur, and K Bendjama, "Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine." AACR. Cancer Research. 2020; 80(16 Suppl): 4566.

CLH Guerrero, Y Yamashita, M Miyara, N Imaizumi, M Kato, S Sakihama, M Hayashi, T Miyagi, K Karimata, J Uchihara, K Ohshiro, J Todoroki, S Nakachi, S Morishima, K Karube, Y Tanaka, H Masuzaki, and T Fukushima, "Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL." Blood advances. 2020; 4(6): 1062-1071.

山下慶子, "個別化がんワクチン療法に向けたAIによるネオアンチゲンの予測", 2019; 第32回日本バイオセラピィ学会学術集会総会

Sverchkova, A., Anzar, I., Stratford, R., & Clancy, T. (2019). Improved HLA typing of Class I and Class II alleles from next‐generation sequencing data. Hla, May, 1–10.

尾上広祐, 山下慶子, Brandon MALONE, 田中雄希, Benoit GRELLIER, Kaidre BENDJAMA, 町田香織, 宇高恵子, "HLA-ペプチド結合予測手法のネオアンチゲンでの評価", 2019; 第23 回日本がん免疫学会総会

Anzar, I., Sverchkova, A., Stratford, R. et al. NeoMutate: an ensemble machine learning framework for the prediction of somatic mutations in cancer. BMC Med Genomics 12, 63 (2019).